薬理と治療

Abstract

Effective and safe therapy has not been established for patients with mixedhyperlipidemia. We conducted two clinical studies in order to clarify significance of combinationtherapy with pitavastatin calcium（hereinafter called PIT）and dextran sulfate sodium sulfur18（hereinafter called DS）and accumulate clinical results of this therapy as supportivedata for daily medical practice. We conducted study 1, comparing three therapies with PIT 2mg QD, DS 300 mg TID and combination of them. Each mono therapy demonstrated reductionin serum triglyceride levels no less than existing reports. On the other hand, efficacy ofcombination therapy of them on that reduction was not significant, which was considered dueto patient back grounds, compliance, and so forth. To improve them, we conducted study 2,adding DS 300 mg QD on PIT 2 mg QD having administered over two months. There wasobserved an additional reduction in triglyceride levels by add−on of DS. In conclusion, it wassuggested that combination therapy with PIT and DS should be positioned with high priorityas an option of pharmacotherapy for patients with mixed hyperdyslipidemia, which is difficultto be managed in daily medical practice.（Jpn Pharmacol Ther 2009；37：587−96）KEY WORDS Mixed hyperlipidemia, Pitavastatin calcium, Dextran sulfate sodium, Multicenterclinical trial, Combination therapy